Race, tumor location, and disease progression among low-risk prostate cancer patients.

Yongmei Chen,Huai‐Ching Kuo,Denise Young,Galen Conti,Inger L Rosner,Sean P Stroup,Allen Burke,Christopher Porter,Isabell Sesterhenn,Kevin R Rice,Grant Williams,William Gesztes,Jennifer Cullen,Samantha A Streicher,Justin G Mygatt

doi:10.1002/cam4.2864

Abstract

BackgroundThe relationship between race, prostate tumor location, and BCR‐free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence‐free (BCR) survival.MethodsA retrospective cohort study was conducted among men with newly diagnosed, biopsy‐confirmed, NCCN‐defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR‐free survival was modeled using Kaplan‐Meier estimation curves and multivariable Cox proportional hazards (PH) analyses.ResultsThere were 539 eligible patients with low‐risk CaP (25% African American, AA; 75% Caucasian American, CA). Median age at CaP diagnosis and post‐RP follow‐up time was 59.2 and 8.1 years, respectively. Kaplan‐Meier analyses showed no significant association between race (P = .52) or predominant tumor location (P = .98) on BCR‐free survival. In Cox PH multivariable analysis, neither race (HR = 1.18; 95% CI = 0.68‐2.02; P = .56) nor predominant tumor location (HR = 1.13; 95% CI = 0.59‐2.15; P = .71) was an independent predictor of BCR‐free survival.ConclusionsNeither race nor predominant tumor location was associated with adverse oncologic outcome.

Highlights

In the United States, prostate cancer (CaP) is the most common form of newly diagnosed nonskin malignancy in males, with an estimated 174 650 new cases in 2019.1 AfricanAmerican (AA) men have consistently been shown to have a higher incidence of CaP compared to Caucasian American (CA) men.[2]
One anatomical feature of the prostate that has been less explored for short- and long-term CaP outcomes, both independently and jointly with race, is predominant tumor location, harboring a predominant anterior tumor could lead to poorer oncologic outcomes for CaP patients, if such tumors are more difficult to detect through standard diagnosis procedures.[7]
A retrospective cohort study was conducted on patients enrolled in the Walter Reed National Military Medical Center (WRNMMC) Biospecimen CaP Repository linked to the Center for Prostate Disease Research (CPDR) Multicenter National Database who self-reported as Caucasian (CA) and African American (AA) and who underwent radical prostatectomy (RP) for treatment of CaP at the WRNMMC between January 1, 1996 and December 31, 2008

Summary

Introduction

In the United States, prostate cancer (CaP) is the most common form of newly diagnosed nonskin malignancy in males, with an estimated 174 650 new cases in 2019.1 AfricanAmerican (AA) men have consistently been shown to have a higher incidence of CaP compared to Caucasian American (CA) men.[2]. One anatomical feature of the prostate that has been less explored for short- and long-term CaP outcomes, both independently and jointly with race, is predominant tumor location, harboring a predominant anterior tumor could lead to poorer oncologic outcomes for CaP patients, if such tumors are more difficult to detect through standard diagnosis procedures.[7]. Both Faisal and colleagues[8] and Tiguert and colleagues[9] found that AA men were more likely to harbor anterior tumors than CA men.[8,9]. Conclusions: Neither race nor predominant tumor location was associated with adverse oncologic outcome

Objectives

Methods

Results

Conclusion